Scilex Holding (SCLX) Q4 2025 earnings summary

Executive summary

• Net revenue for 2025 was $30.3 million, down from $56.6 million in 2024, driven by lower sales of ZTlido and ELYXYB, and a slight decrease in GLOPERBA sales, with GLOPERBA launched in June 2024.

• The company reported a net loss of $374.1 million in 2025, compared to a net loss of $72.8 million in 2024, with an accumulated deficit of $921.8 million as of year-end 2025.

• Operating expenses increased significantly to $376.3 million in 2025, primarily due to a $73.4 million goodwill impairment related to the Vivasor acquisition and $148.7 million in costs related to the Semnur reverse recapitalization and other financing activities.

• Cash and cash equivalents at year-end 2025 were $5.0 million, with negative working capital of $445.3 million and substantial doubt about the company’s ability to continue as a going concern.

Financial highlights

• Net revenue declined 46% year-over-year, primarily due to decreased sales volume and higher rebates.

• Cost of revenue decreased to $10.6 million from $16.7 million, reflecting lower sales.

• Research and development expenses more than doubled to $20.7 million, driven by higher costs for SP-102 and new development projects.

• Selling, general and administrative expenses rose to $266.9 million, up from $119.0 million, mainly due to transaction and advisory costs.

• Goodwill impairment of $73.4 million was recorded for the Vivasor acquisition.

• Significant realized and unrealized losses on digital assets totaled $42.4 million.

• Interest expense increased to $11.5 million, reflecting higher debt levels.

Outlook and guidance

• Management expects continued net losses and negative cash flows, with ongoing investments in sales, marketing, and R&D for ZTlido, GLOPERBA, ELYXYB, and pipeline candidates.

• The company plans to seek additional funding through equity, debt, collaborations, or strategic transactions, but there is substantial doubt about its ability to continue as a going concern.

• Future liquidity is highly dependent on successful commercialization of current products and the ability to raise capital.